Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

872
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
872
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

745
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
745
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

689
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
689
Cancer Therapies02:49

Cancer Therapies

8.1K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paclitaxel plus cetuximab for the treatment of R/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trial.

ESMO open·2026
Same author

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy.

IJTLD open·2025
Same author

Soluble PD-L1 shows no association to relapse and overall survival in early stage non-small cell lung cancer (NSCLC).

Lung cancer (Amsterdam, Netherlands)·2024
Same author

Patients with cancer who will be cured and projections of complete prevalence in Italy from 2018 to 2030.

ESMO open·2024
Same author

Robotic surgery versus conventional laparoscopy in sigmoid colectomy for diverticular disease-a comparison of operative trauma and cost-effectiveness: retrospective, single-center analysis.

Langenbeck's archives of surgery·2024
Same author

Emergency reconstruction of extensor terminal slip defect by tendon plasty.

Hand surgery & rehabilitation·2023
Same journal

The Relevance of Cancer-Type-Specific Scenarios in Predicting Primary Radiotherapy Use in Nonmetastatic Cancer Patients in the Netherlands Towards 2032.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Current Practice for Electronic Medical Device Management in Radiation Therapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

The Application of AI in Cancer MDT and its Legal Implication.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Research Trends in Physical Activity and Breast Cancer: A 25-Year Bibliometric Analysis (2000-2025).

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Concordance Between Planned and Delivered treatment for Head and Neck Cancer Patients Treated With Curative Intent: A Real-World Comparison of Under 70-year-olds With 70-year-olds and Over.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

A Novel Technique for Pain Management to Deliver a Course of Palliative Radiotherapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
See all related articles

Related Experiment Video

Updated: Apr 28, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K

R-CHOP versus R-COMP: are they really equally effective?

M Mian1, I Wasle1, G Gamerith1

  • 1Department of Hematology & Oncology, Medical University of Innsbruck, Innsbruck, Austria.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|June 16, 2014
PubMed
Summary
This summary is machine-generated.

The R-CHOP regimen is standard for diffuse large B-cell lymphoma (DLBCL). Replacing doxorubicin with liposomal doxorubicin in R-COMP showed comparable efficacy and complete remission rates in DLBCL patients.

Keywords:
Diffuse large B-cell lymphomaR-CHOPR-COMPoutcome

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

11.8K

Related Experiment Videos

Last Updated: Apr 28, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

11.8K

Area of Science:

  • Oncology
  • Hematology
  • Clinical Pharmacology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is a common non-Hodgkin lymphoma.
  • The standard first-line treatment is R-CHOP, which carries a risk of cardiotoxicity.
  • Liposomal doxorubicin may reduce cardiotoxicity, but its efficacy compared to R-CHOP is not well-established.

Purpose of the Study:

  • To compare the efficacy and safety of R-CHOP versus R-COMP (using liposomal doxorubicin) as first-line treatment for DLBCL.
  • To evaluate complete remission rates and survival outcomes between the two regimens.
  • To assess the potential of liposomal doxorubicin as a less cardiotoxic alternative in DLBCL treatment.

Main Methods:

  • Retrospective analysis of 364 consecutive DLBCL patients treated with first-line R-CHOP or R-COMP.
  • Comparison of complete remission rates, overall survival, and progression-free survival.
  • Statistical analysis to determine the significance of observed differences.

Main Results:

  • Both R-CHOP and R-COMP regimens demonstrated high and comparable rates of complete remission in DLBCL patients.
  • The study provides evidence that both treatments are effective in curing DLBCL.
  • No significant differences in efficacy were observed between the two treatment arms.

Conclusions:

  • First-line R-COMP, utilizing liposomal doxorubicin, is as effective as R-CHOP in achieving complete remission and curing DLBCL.
  • Liposomal doxorubicin represents a viable alternative in first-line DLBCL treatment, potentially mitigating cardiotoxicity.
  • Further confirmatory studies are warranted to solidify these findings.